(Q37831995)

24 August 2017

What principles should govern the use of managed entry agreements? (English)

1 reference

24 August 2017

Marianne Klemp

1

1 reference

24 August 2017

Katrine B Frønsdal

series ordinal

2

1 reference

24 August 2017

Karen Facey

series ordinal

3

1 reference

24 August 2017

HTAi Policy Forum

series ordinal

4

1 reference

24 August 2017

25 January 2011

1 reference

International Journal of Technology Assessment in Health Care

24 August 2017

1 reference

24 August 2017

27

1 reference

24 August 2017

1

1 reference

24 August 2017

77-83

1 reference

Comparative effectiveness research: a report from the Institute of Medicine.

24 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

Access with evidence development schemes: a framework for description and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

We know accurately only when we know little

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Spending on new drug development1

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Accountability for reasonableness: an update

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Access with evidence development: the US experience

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

How to improve R&D productivity: the pharmaceutical industry's grand challenge

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Coverage with evidence development: an examination of conceptual and policy issues

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Access with evidence development in the UK: past experience, current initiatives and future potential.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes

1 reference

https://api.crossref.org/works/10.1017%2FS0266462310001297

7 January 2021

10.1017/S0266462310001297

Identifiers

DOI

1 reference

24 August 2017

1 reference